Voyager Therapeutics Stock Price To Earning
| VYGR Stock | USD 5.78 0.11 1.94% |
Voyager Therapeutics fundamentals help investors to digest information that contributes to Voyager Therapeutics' financial success or failures. It also enables traders to predict the movement of Voyager Stock. The fundamental analysis module provides a way to measure Voyager Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Voyager Therapeutics stock.
Voyager | Price To Earning |
Voyager Therapeutics Company Price To Earning Analysis
Voyager Therapeutics' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Voyager Therapeutics Price To Earning | 5.62 X |
Most of Voyager Therapeutics' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Voyager Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Voyager Price To Earning Driver Correlations
Understanding the fundamental principles of building solid financial models for Voyager Therapeutics is extremely important. It helps to project a fair market value of Voyager Stock properly, considering its historical fundamentals such as Price To Earning. Since Voyager Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Voyager Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Voyager Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Voyager Retained Earnings
Retained Earnings |
|
Based on the latest financial disclosure, Voyager Therapeutics has a Price To Earning of 5.62 times. This is 78.25% lower than that of the Biotechnology sector and 14.0% higher than that of the Health Care industry. The price to earning for all United States stocks is 80.43% higher than that of the company.
Voyager Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Voyager Therapeutics' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Voyager Therapeutics could also be used in its relative valuation, which is a method of valuing Voyager Therapeutics by comparing valuation metrics of similar companies.Voyager Therapeutics is currently under evaluation in price to earning category among its peers.
Voyager Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Voyager Therapeutics from analyzing Voyager Therapeutics' financial statements. These drivers represent accounts that assess Voyager Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Voyager Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 500.8M | 265.5M | 102.1M | 363.1M | 326.8M | 228.4M | |
| Enterprise Value | 448.9M | 208.7M | 28.8M | 314.6M | 283.1M | 197.9M |
Voyager Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Voyager Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Voyager Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Voyager Fundamentals
| Return On Equity | 0.1 | ||||
| Return On Asset | 0.0157 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | (0.56) % | ||||
| Current Valuation | 15.72 M | ||||
| Shares Outstanding | 54.63 M | ||||
| Shares Owned By Insiders | 16.98 % | ||||
| Shares Owned By Institutions | 65.40 % | ||||
| Number Of Shares Shorted | 2.44 M | ||||
| Price To Earning | 5.62 X | ||||
| Price To Book | 0.96 X | ||||
| Price To Sales | 1.93 X | ||||
| Revenue | 250.01 M | ||||
| Gross Profit | (19.86 M) | ||||
| EBITDA | 126.45 M | ||||
| Net Income | 132.33 M | ||||
| Cash And Equivalents | 148.06 M | ||||
| Cash Per Share | 3.83 X | ||||
| Total Debt | 20.29 M | ||||
| Debt To Equity | 0.40 % | ||||
| Current Ratio | 1.55 X | ||||
| Book Value Per Share | 6.06 X | ||||
| Cash Flow From Operations | 77.92 M | ||||
| Short Ratio | 3.55 X | ||||
| Earnings Per Share | 0.66 X | ||||
| Target Price | 17.22 | ||||
| Number Of Employees | 162 | ||||
| Beta | 0.89 | ||||
| Market Capitalization | 315.74 M | ||||
| Total Asset | 351.28 M | ||||
| Retained Earnings | (261.18 M) | ||||
| Working Capital | 255.18 M | ||||
| Current Asset | 195.89 M | ||||
| Current Liabilities | 23.93 M | ||||
| Net Asset | 351.28 M |
About Voyager Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Voyager Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Voyager Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Voyager Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Voyager Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Voyager Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Voyager Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Voyager Stock
Moving against Voyager Stock
The ability to find closely correlated positions to Voyager Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Voyager Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Voyager Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Voyager Therapeutics to buy it.
The correlation of Voyager Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Voyager Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Voyager Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Voyager Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Voyager Stock Analysis
When running Voyager Therapeutics' price analysis, check to measure Voyager Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyager Therapeutics is operating at the current time. Most of Voyager Therapeutics' value examination focuses on studying past and present price action to predict the probability of Voyager Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyager Therapeutics' price. Additionally, you may evaluate how the addition of Voyager Therapeutics to your portfolios can decrease your overall portfolio volatility.